Therefore, special attention has been devoted over past years to food- intake-lowering peptides employed for the treatment of both diabetes and obesity as PrRP as potential disease-modifying drugs for AD [52]. This evidence concerns the gene PRLH and obesity due to melanocortin 4 receptor deficiency.